Anne Rabbitte

And I think if I was to make one call with on the Taoiseach or the Minister for Health.

within their EU presidency.

We should be prioritising this.

We should come out of our EU presidency with having put in place a collective where we can do national bargaining when it comes to orphan drugs and rare diseases, because someday a drug will be produced here and we might have only one because of our size of a population.

And Professor Michael Barry will turn and say he can't approve.

And the senior management will say they can't approve because of the cost basis of it.

And we then need to be able to collectively work with all of our other counterparts in Europe for that small percentage to be able to deliver for people.

I can't put a price on a life.

I don't think it's right that we should be saying to Professor Barry, you have to as well.

I think we need to do collective bargaining right across the EU.

particularly when it comes to kids, because I also look at the whole purpose around children and equity of access.

We have to look at the whole equity of access, the rights of the child.

And are we denying the child the right of access?

Because their voice has never been heard till they're 18.

It's all like there's a whole piece there, I think, within EU legislation that should be looked at, Clare.

Maybe they'll sit back a little bit, and I'm not saying it about Biogen, maybe they'll sit back and hope that the families will drive such a successful campaign that they'll end up getting what they set out as the bottom line.

I would hope not in this case.

I would hope that the drug companies, and we have great drug companies here, we are at the centre of it, I would hope the drug companies would see it as this early access opportunity here

that we can show that this drug works and it delivers.

And we would want them to be producing more of it because more countries who are not in that zone at the moment purchasing would want to purchase.